Literature DB >> 27179206

Circulating endothelial microparticles are elevated in bicuspid aortic valve disease and related to aortic dilation.

Josep M Alegret1, Neus Martínez-Micaelo2, Gerard Aragonès2, Raúl Beltrán-Debón2.   

Abstract

BACKGROUND/
OBJECTIVES: The mechanisms underlying aortic dilation in bicuspid aortic valve (BAV) disease are unknown. Circulating endothelial microparticles (EMPs) have emerged as biomarkers of endothelial damage. We sought to evaluate the relationships among EMPs, BAV disease, and aortic dilation.
METHODS: Four evaluations were used. Circulating EMPs (PECAM(+), E-selectin(+)) were compared between BAV patients and tricuspid aortic valve (TAV) control subjects. The variables related to circulating EMPs were investigated in BAV patients. Circulating EMP levels were compared between BAV and TAV patients with a dilated aorta. Finally, circulating EMPs in BAV patients were evaluated over time with respect to aortic valve surgery (AVS) or aortic surgery.
RESULTS: We observed higher levels of circulating PECAM(+) EMPs in the BAV patients than in the control subjects (3.98±0.2 vs. 2.39±0.4 per log PECAM(+) EMPs/μl, p=0.001). Aortic dilation was the most significant variable that correlated with the PECAM(+) EMP levels in the BAV patients (β=0.321, p=0.008). The BAV patients with aortic dilation exhibited higher PECAM(+)EMP levels than the TAV patients with dilated aortas, and this correlation was independent of aortic valve function. We observed a drastic decrease in the circulating PECAM(+) EMPs following AVS and aortic root replacement (4.27±0.6 and 1.75±0.3 per log PECAM(+)EMPs/μl, p=0.002).
CONCLUSION: The observed pattern of higher circulating PECAM(+) EMP levels links BAV disease to endothelial damage and aortic dilation. Circulating PECAM(+) EMPs were identified as a biological variable related to aortic dilation in patients with BAV disease.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Aortic dilation; Aortic root; Ascending aorta; Bicuspid aortic valve; Endothelial microparticles

Mesh:

Substances:

Year:  2016        PMID: 27179206     DOI: 10.1016/j.ijcard.2016.04.184

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  6 in total

Review 1.  Genetic and Developmental Contributors to Aortic Stenosis.

Authors:  Punashi Dutta; Jeanne F James; Hail Kazik; Joy Lincoln
Journal:  Circ Res       Date:  2021-04-29       Impact factor: 17.367

2.  MicroRNAs Clustered within the 14q32 Locus Are Associated with Endothelial Damage and Microparticle Secretion in Bicuspid Aortic Valve Disease.

Authors:  Neus Martínez-Micaelo; Raúl Beltrán-Debón; Gerard Aragonés; Marta Faiges; Josep M Alegret
Journal:  Front Physiol       Date:  2017-09-05       Impact factor: 4.566

3.  Endothelial Colony Forming Cells as an Autologous Model to Study Endothelial Dysfunction in Patients with a Bicuspid Aortic Valve.

Authors:  Vera van de Pol; Lidia R Bons; Kirsten Lodder; Konda Babu Kurakula; Gonzalo Sanchez-Duffhues; Hans-Marc J Siebelink; Jolien W Roos-Hesselink; Marco C DeRuiter; Marie-José Goumans
Journal:  Int J Mol Sci       Date:  2019-07-02       Impact factor: 5.923

Review 4.  Endothelial/Epithelial Mesenchymal Transition in Ascending Aortas of Patients With Bicuspid Aortic Valve.

Authors:  Shohreh Maleki; Flore-Anne Poujade; Otto Bergman; Jesper R Gådin; Nancy Simon; Karin Lång; Anders Franco-Cereceda; Simon C Body; Hanna M Björck; Per Eriksson
Journal:  Front Cardiovasc Med       Date:  2019-12-17

5.  Data on the circulating levels of endothelial microparticles are elevated in patients with bicuspid aortic valve and are related to aortic dilation.

Authors:  Josep M Alegret; Neus Martínez-Micaelo; Gerard Aragonès; Raúl Beltrán-Debón
Journal:  Data Brief       Date:  2016-06-23

Review 6.  Thoracic Aortic Aneurysm Development in Patients with Bicuspid Aortic Valve: What Is the Role of Endothelial Cells?

Authors:  Vera van de Pol; Kondababu Kurakula; Marco C DeRuiter; Marie-José Goumans
Journal:  Front Physiol       Date:  2017-11-30       Impact factor: 4.566

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.